Prodrugs of pioglitazone for extended-release (XR) injectable formulations

Molecular Pharmaceutics

Volumn 11, Issue 10, 2014, Pages 3617-3623

  Sanrame, Carlos N ^a   Remenar, Julius F ^a   Blumberg, Laura C ^a   Waters, Julie ^a   Dean, Reginald L ^a   Dong, Nan ^a   Kriksciukaite, Kristi ^a,c   Cao, Peixin ^a   Almarsson, Örn ^a,b  

^a Alkermes Plc   (United States)

^b MODERNA THERAPEUTICS   (United States)

^c Blend Therapeutics   (United States)

Author keywords

diabetes; extended release; long acting injectable (LAI); N acyloxy derivatives; pioglitazone prodrugs; prodrugs; solid state NMR

Indexed keywords

BUTYROYLOXYMETHYL; ESTER; HEXANOYLOXYMETHYL; LAUROYLOXYMETHYL; MYRISTOYLOXYMETHYL; OLEIC ACID ETHYL ESTER; PALMITOYLOXYMETHYL; PIOGLITAZONE; PRODRUG; SODIUM CHLORIDE; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE;

ANIMAL EXPERIMENT; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CARBON NUCLEAR MAGNETIC RESONANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CONFORMATION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; IN VITRO STUDY; IN VIVO STUDY; LIPOPHILICITY; MELTING POINT; NONHUMAN; PROTEIN CLEAVAGE; RAT; ROOM TEMPERATURE; SOLID; SUSTAINED RELEASE FORMULATION; X RAY POWDER DIFFRACTION; ANIMAL; CHEMISTRY; MEDICINAL CHEMISTRY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; SOLUBILITY; X RAY DIFFRACTION;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; MAGNETIC RESONANCE SPECTROSCOPY; PRODRUGS; RATS; SOLUBILITY; THIAZOLIDINEDIONES; X-RAY DIFFRACTION;

EID: 84907992404     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp500359a     Document Type: Article

References (33)

1. Scheen, A. J. Hepatotoxicity with thiazolidinediones: is it a class effect? Drug Saf. 2001, 24, 873-888
2. Rasouli, N.; Raue, U.; Miles, L. M.; Lu, T.; Di Gregorio, G. B.; Elbein, S. C.; Kern, P. A. Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue Am. J. Physiol.: Endocrinol. Metab. 2005, 288 (5) E930-934
3. Tobiasova, Z.; Zhang, L.; Yi, T.; Qin, L.; Manes, T. D.; Kulkarni, S.; Lorber, M. I.; Rodriguez, F. C.; Choi, J.-M.; Tellides, G.; Pober, J. S.; Kawikova, I.; Bothwell, A. L. M. Peroxisome proliferator-activated receptor-γ agonists prevent in vivo remodeling of human artery induced by alloreactive T cells Circulation 2011, 124, 196-205
4. Li, W.; Macdonald, T. M.; Mackenzie, I. S. Pioglitazone and bladder cancer: A propensity score matched cohort study Br. J. Clin. Pharmacol. 2013, 75, 254-259
5. Cañas, F.; Möller, H. J. Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review Expert Opin. Drug Saf. 2010, 9, 683-697
6. Baser, O.; Chalk, M.; Rawson, R.; Gastfriend, D. R. Alcohol dependence treatments: comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence Am. J. Manag. Care 2011, Suppl. 8, S222-S234
7. Woo, H. J.; Kim, J. S.; Nurunnabi, M.; Huh, K. M.; Cho, K. J.; Lee, Y. Preparation and characterization of pioglitazone loaded PLGA nanospheres for the treatment of type 2 diabetes Polymer 2010, 34, 527-533
8. Merisko-Liversidge, E.; Liversidge, G. G. Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology Adv. Drug Delivery Rev. 2011, 63, 427-440
9. Remenar, J. F. Making the leap from daily oral dosing to long acting injectables: lessons from the antipsychotics Mol. Pharmaceutics. 2014, 11, 1739-1749
10. Remenar, J. F.; Blumberg, L. C.; Zeidan, T. A. Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders. U.S. Patent 8,431,576, 30 April 30, 2013.
11. Blumberg, L. C.; Zeidan, T. A.; Maddaford, A.; Warren, N. C.; Hutchison, P. Novel N-5-(acyloxyalkoxy)carbonyl prodrugs of olanzapine with physicochemical properties for extended-release RSC Adv. 2013, 3, 16270-16278
12. Wright, J. C.; Burgess, D. J., Eds. Long Acting Injections and Implants. In Advances in Delivery Science and Technology; Springer: New York, 2012.
13. Turncliff, R.; Potocka, E.; Corey, L.; Lowy, A.; Marandi, M.; DeSomer, M.; Ehrich, E. ALKS 9070, a novel once monthly prodrug of aripiprazole, achieves therapeutic levels and is well-tolerated in adults with schizophrenia Eur. Neuropsychopharmacol. 2012, 22 (Supplement 3) S330-S331
14. Guarino, V. R.; Stella, V. J. Prodrugs of Amides, Imides and Other NH-Acidic Compounds. In Prodrugs: Challenges and Rewards, Part 2; Stella, V. J.; Borchardt, R. T.; Hageman, M. J.; Oliyai, R.; Maag, H.; Tilley, J. W., Eds.; Springer: New York, 2007; pp 133-187.
15. Bundgaard, H. Formation of prodrugs of amines, amides, ureides, and imides Method Enzymol. 1985, 112, 347-359
16. Stella, V. J.; Martodihardjo, S.; Terada, K.; Rao, V. M. Some relationships between the physical properties of various 3-acyloxymethyl prodrugs of phenytoin to structure: potential in vivo performance implications J. Pharm. Sci. 1998, 87, 1235-1241
17. Gerber, N.; Mays, D. C.; Donn, K. H.; Laddu, A.; Guthrie, R. M.; Turlapaty, P.; Quon, C. Y.; Rivenburg, W. K. Safety, tolerance and pharmacokinetics of intravenous doses of the phosphate ester of 3-hydroxymethyl-5,5-diphenylhydantoin: a new prodrug of phenytoin J. Clin. Pharmacol. 1988, 28, 1023-1032
18. While formaldehyde is a known carcinogen, prodrugs known to release formaldehyde at relatively low levels have been shown to be safe: Griesemer, R.; Ulsamer, A.; Arcos, J.; Beall, J.; Blair, A.; Collins, T.; de Serres, F.; Everson, R.; Gamble, J.; Gaylor, D.; Groth, D.; Kang, J.; Keenlyside, R.; Lloyd, J.; Nettesheim, P.; Saffiotti, U.; Weisburger, E. Report of the federal panel on formaldehyde Environ. Health Perspect. 1982, 43, 139-168
19. Dhareshwar, S. S.; Stella, V. J. Your prodrug releases formaldehyde: should you be concerned? No! J. Pharm. Sci. 2008, 97, 4184-4193
20. Bundgaard, H.; Johansen, M. Prodrugs as drug delivery systems. VIII. Bioreversible derivatization of hydantoins by N-hydroxymethylation Int. J. Pharm. 1980, 5, 67-77
21. Johansen, M.; Bundgaard, H. Prodrugs as drug delivery systems. VI. Kinetics and mechanism of the decomposition of the N-hydroxymethylated amides and imides in aqueous solutions and assessment of their suitability as possible prodrugs Arch. Pharm. Chemi, Sci. Ed. 1979, 7, 175-192
22. Al-Arfaj, N. A.; Al-Abdulkareem, E. A.; Aly, F. A. A validated adsorptive stripping voltammetric determination of antidiabetic agent pioglitazone HCl in tablets and biological fluids Int. J. Biomed. Sci. 2008, 4, 310-318
23. Ulich, L. H.; Adams, R. The reaction between acid halides and aldehydes III J. Am. Chem. Soc. 1921, 43, 660-667
24. Finkelstein, H. Ber. Dtsch. Chem. Ges. 1910, 43, 1528-1532
25. National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Guide for the Care and Use of Laboratory Animals, 8 th ed.; National Academies Press (US): Washington, DC, 2011.
26. Tishmack, P. A.; Bugay, D. E.; Byrn, S. R. Solid-state nuclear magnetic resonance spectroscopy-pharmaceutical applications J. Pharm. Sci. 2003, 92, 441-474
27. Geppi, M.; Mollica, G.; Borsacchi, S.; Veracini, C. A. Solid-state NMR studies of pharmaceutical systems Appl. Spectrosc. Rev. 2008, 43, 202-302
28. Berendt, R. T.; Sperger, D. M.; Munson, E. J.; Isbester, P. K. Solid-state NMR spectroscopy in pharmaceutical research and analysis TrAC, Trends Anal. Chem. 2006, 25, 977-984
29. Patton, J. S.; Stone, B.; Papa, C.; Abramowitz, R.; Yalkowsky, S. H. Solubility of fatty acids and other hydrophobic molecules in liquid trioleoylglycerol J. Lipid Res. 1984, 25, 189-97
30. Liederer, B. M.; Borchardt, R. T. Enzymes involved in the bioconversion of ester-based prodrugs J. Pharm. Sci. 2006, 95, 1177-1195
31. Satoh, T.; Hosokawa, M. The mammalian carboxylesterases: from molecules to functions Annu. Rev. Pharmacol. Toxicol. 1998, 38, 257-288
32. Ross, M. K.; Crow, J. A. Human carboxylesterases and their role in xenobiotic and endobiotic metabolism J. Biochem. Mol. Toxicol. 2007, 21, 187-196
33. Yamaoka, Y.; Roberts, R. D.; Stella, V. J. Low-melting phenytoin prodrugs as alternative oral delivery modes for phenytoin: a model for other high melting sparingly water-soluble drugs J. Pharm. Sci. 1983, 72, 400-405